Press Releases

12345678910
K1x and Juno Announce Strategic Partnership to Provide Industry-Leading Tax Automation
K1x, the tax data operations solution for private markets, today announced a strategic partnership with Juno, a modern tax preparation, review, and advisory platform built by CPAs for the realities of practice life. The partnership introduces a new integration that enables automated K-1 data to flow directly into Juno, powered by patented K1x technology.
By K1x Inc. · Via Business Wire · January 8, 2026
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026.
By Enanta Pharmaceuticals, Inc. · Via Business Wire · January 8, 2026
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine.
By Virometix AG · Via Business Wire · January 8, 2026
LegalMatch.com Highlights Urgent Need for Legal Guidance as Drone Regulations Evolve
Hobbyists and Small Businesses Must Navigate FAA Rules, Local Ordinances, and Privacy Concerns
Via ACCESS Newswire · January 8, 2026
EAGLE FOOTBALL GROUP : ERRATUM DISCLOSURE OF TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES IN THE CAPITAL AT JULY 31, 2025
Via Actus News · January 8, 2026
EAGLE FOOTBALL GROUP : ERRATUM DÉCLARATION D'ACTIONS ET NOMBRE DE DROITS DE VOTE AU 31 JUILLET 2025
Via Actus News · January 8, 2026
SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-expansion portion of the Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral (AAV) vector gene therapy for the treatment of Stargardt disease.
By SpliceBio · Via Business Wire · January 8, 2026
Concord Appoints Chris Baker as Executive Chairman
Concord, an H.I.G. Capital portfolio company and leading provider of technology and digital transformation solutions, today announced the appointment of Chris Baker as Executive Chairman.
By Concord · Via Business Wire · January 8, 2026
TD SYNNEX Reports Record Fiscal 2025 Fourth Quarter Results
TD SYNNEX (NYSE: SNX) today announced financial results for the fiscal fourth quarter ended November 30, 2025.
By TD SYNNEX · Via Business Wire · January 8, 2026
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance.
By Indivior Inc. · Via GlobeNewswire · January 8, 2026
EAGLE FOOTBALL GROUP : ERRATUM : DECLARATION D'ACTIONS ET NOMBRE DE DROITS DE VOTE AU 30 JUIN 2025
Via Actus News · January 8, 2026
EAGLE FOOTBALL GROUP : ERRATUM DISCLOSURE OF TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES IN THE CAPITAL AT JUNE 30, 2025
Via Actus News · January 8, 2026
U.S. Army Selects Striveworks for AI Test and Evaluation
Striveworks, a leading developer of cutting-edge artificial intelligence solutions, has been selected to provide AI test and evaluation services for the U.S. Army under a Phase II Small Business Innovation Research (SBIR) award. Striveworks’ AI operations (AIOps) platform will standardize and scale the test and evaluation of AI models. This is a critical step in deploying secure and reliable AI capabilities aligned with Army modernization priorities.
By Striveworks · Via Business Wire · January 8, 2026
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.
By AstraZeneca · Via Business Wire · January 8, 2026
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
Initial study will enable further collaboration on the predictive capabilities of StemPrintER
By AccuStem Sciences, Inc. · Via GlobeNewswire · January 8, 2026
BitMEX Report Finds Crypto Perpetuals Enter Post-Yield Era
State of Crypto Perpetual Swaps 2025 details market stress, trust gaps and new derivatives trends
By BitMEX · Via GlobeNewswire · January 8, 2026
CMR Surgical receives CE Mark for use of Versius in paediatric surgery
CMR Surgical receives CE Mark for use of Versius in paediatric surgery
By CMR Surgical · Via GlobeNewswire · January 8, 2026
Anika Therapeutics Announces Leadership Transition
BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griffin will succeed Cheryl R. Blanchard, Ph.D., who will become Executive Chair of the Board of Directors. In addition, John (Jack) B. Henneman, III, Director since 2020, has been appointed Lead Independent Director.
By Anika Therapeutics Inc. · Via GlobeNewswire · January 8, 2026
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data
By Cullinan Therapeutics, Inc. · Via GlobeNewswire · January 8, 2026
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026
By Atea Pharmaceuticals, Inc. · Via GlobeNewswire · January 8, 2026
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –
By Entrada Therapeutics, Inc. · Via GlobeNewswire · January 8, 2026
Surge Copper Advances Berg Toward Pre-Feasibility with Successful 2025 Drilling and Data Validation Program
Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to report results from its 2025 multidisciplinary drilling and field program at the 100%-owned Berg Project in central British Columbia. The program was designed to advance Berg toward completion of a Pre-Feasibility Study (“PFS”) planned for H1-2026 (see November 19, 2025 press release), and was successfully executed with a focus on resource category conversion, validation of historic drilling through modern QA/QC procedures, acid rock drainage characterization, and geotechnical investigations for planned mine infrastructure.
By Surge Copper Corp. · Via GlobeNewswire · January 8, 2026
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat.
By Sagimet Biosciences Inc. · Via GlobeNewswire · January 8, 2026
Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target
MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is very pleased to announce a maiden, open-pit Mineral Inferred Resource Estimate (“MRE”) of 52.2 million tonnes (“Mt”) grading 1.08% Li2O and 131ppm Ta2O5 for its wholly owned Mirage Project located in the Eeyou Istchee Baie-James region of Quebec, Canada (see Figure 1). The MRE was prepared in accordance with the National Instrument (“NI”) 43-101 standards by PLR Resource Inc. and Synectiq Inc.
By Brunswick Exploration · Via GlobeNewswire · January 8, 2026
Troilus Delivers on Key Development Milestones in 2025 and Enters a Pivotal Transition Year in 2026
MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Troilus Mining Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5) (“Troilus” or the “Company”), is pleased to provide a review of its key accomplishments in 2025 and an outlook for 2026, as the Company advances its flagship Troilus copper-gold project (the “Project”) through critical development milestones and positions it for the next phase of execution, in this open letter to shareholders from Chief Executive Officer, Justin Reid. To our valued shareholders and stakeholders,
By Troilus Gold Corp. · Via GlobeNewswire · January 8, 2026
Kinross to provide update on Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Kinross Gold Corporation (TSX: K; NYSE: KGC) (“Kinross”) will provide an update on its Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects, followed by a virtual presentation and question and answer session at 9:00 a.m. EST on Thursday, January 15, 2026.
By Kinross Gold Corporation · Via GlobeNewswire · January 8, 2026
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
Dr. Duda to apply deep expertise in rare and immune-mediated diseases
By GlycoEra · Via GlobeNewswire · January 8, 2026
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026 in San Francisco, California.
By AAVantgarde · Via GlobeNewswire · January 8, 2026
Woof Gang Achieves Record Growth in 2025
America’s largest pet grooming brand reports 25% YoY sales increase; doubles its footprint in three years
By Woof Gang Bakery & Grooming · Via GlobeNewswire · January 8, 2026
ONAR Completes Sale of Certain Legacy Assets in a Secured $1.5 Million Seller-Financed Transaction
The agreement converts certain legacy assets into a structured payment obligation supported by collateral and a personal guaranty, while expressly excluding intellectual property related to the ‘Of Kos’ brand from the sale. The transaction closed December 31, 2025 and became effective as of December 30, 2025
By ONAR Holding Corporation · Via GlobeNewswire · January 8, 2026
Aurora Mobile Congratulates Zhipu on Successful Hong Kong Listing
SHENZHEN, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today extended its congratulations to Knowledge Atlas Technology Joint Stock Company Limited, also known as Zhipu, on its successful listing on the Main Board of the Stock Exchange of Hong Kong.
By Aurora Mobile Limited · Via GlobeNewswire · January 8, 2026
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 
By Climb Bio, Inc. · Via GlobeNewswire · January 8, 2026
Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million
LONDON and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that it has raised over $75 million in an oversubscribed Series C financing led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of Foundation Fighting Blindness. Beacon’s existing investors, Syncona Limited, Forbion, Oxford Science Enterprises, and Advent Life Sciences, also participated in the round.
By Beacon Therapeutics (USA), Inc. · Via GlobeNewswire · January 8, 2026
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026.
By AtaiBeckley N.V. · Via GlobeNewswire · January 8, 2026
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets
By Amarin Corporation plc · Via GlobeNewswire · January 8, 2026
Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS
Company Expects to Report Topline Data in Q4 2026
By Tisento Therapeutics Inc · Via GlobeNewswire · January 8, 2026
Clough Global Opportunities Fund Declares Monthly Distributions For Q1 2026, Increasing Its Distribution By 7.2% To $0.0537 Per Share; Announces Market Update Conference Call
DENVER, CO / ACCESS Newswire / January 8, 2026 / Today, Clough Global Opportunities Fund (NYSE American:GLO) (the "Fund") declared monthly cash distributions of $0.0537 per common share, payable on the dates noted below. These distributions represent a 7.2% increase from the Fund's prior distributions and are made under the Fund's managed distribution policy, which is intended to provide shareholders with a consistent monthly distribution at a rate of at least one-twelfth of 10% of the Fund's average net asset value ("NAV") per share for the last five business days of the prior calendar year.
Via ACCESS Newswire · January 8, 2026
Clough Global Equity Fund Declares Monthly Distributions for Q1 2026, Increasing its Distribution by 12.2% to $0.0729 Per Share; Announces Market Update Conference Call
DENVER, CO / ACCESS Newswire / January 8, 2026 / Today, Clough Global Equity Fund (NYSE American:GLQ) (the "Fund") declared monthly cash distributions of $0.0729 per common share, payable on the dates noted below. These distributions represent a 12.2% increase from the Fund's prior distributions and are made under the Fund's managed distribution policy, which is intended to provide shareholders with a consistent monthly distribution at a rate of at least one-twelfth of 10% of the Fund's average net asset value ("NAV") per share for the last five business days of the prior calendar year.
Via ACCESS Newswire · January 8, 2026
Clough Global Dividend and Income Fund Declares Monthly Distributions for Q1 2026, Increasing Its Distribution by 7.6% to $0.0566 Per Share; Announces Market Update Conference Call
DENVER, CO / ACCESS Newswire / January 8, 2026 / Today, Clough Global Dividend and Income Fund (NYSE American:GLV) (the "Fund") declared a monthly cash distribution of $0.0566 per common share, payable on the dates noted below. These distributions represent a 7.6% increase from the Fund's prior distributions and are made under the Fund's managed distribution policy, which is intended to provide shareholders with a consistent monthly distribution at a rate of at least one-twelfth of 10% of the Fund's average net asset value ("NAV") per share for the last five business days of the prior calendar year.
Via ACCESS Newswire · January 8, 2026
How Third-Party Platforms Are Improving Top-Up Transparency for Gamers
BuffBuff is changing how players understand digital purchases, especially as video gaming grows more connected and more global. In the past, players often felt confused when buying in-game currency. Prices changed quickly, and rules were unclear. However, reliable third-party platforms have slowly improved this experience. Because of better systems and clearer rules, players now feel safer and more informed before spending money.
Via PulseBulletin.com · January 8, 2026
First Foundation Inc. Announces Fourth Quarter 2025 Earnings Release Details
First Foundation Inc. (NYSE: FFWM) (“First Foundation”), a financial services company with two wholly owned operating subsidiaries, First Foundation Advisors and First Foundation Bank, announced today that it will release its fourth quarter 2025 earnings results before the market opens on Thursday, January 29, 2026.
By First Foundation Inc. · Via Business Wire · January 8, 2026
Adam Clermont Releases New Book – Profit Before People: When Corporations Knew It Was Dangerous and Sold It Anyway
Via PRLog · January 8, 2026
The Buckle, Inc. Reports December 2025 Net Sales
The Buckle, Inc. (NYSE: BKE) announced today that comparable store net sales, for stores open at least one year, for the 5-week period ended January 3, 2026 increased 5.5 percent from comparable store net sales for the 5-week period ended January 4, 2025. Net sales for the 5-week fiscal month ended January 3, 2026 increased 6.5 percent to $215.3 million from net sales of $202.1 million for the prior year 5-week fiscal month ended January 4, 2025.
By The Buckle, Inc. · Via Business Wire · January 8, 2026
RentRedi Recognized for Premier Customer Service by National Association of Realtors®
The NAR REALTOR Benefits® Customer Experience Award celebrates RentRedi’s impact on real estate agents who advise rental investors and operate their own rental businesses
By RentRedi · Via GlobeNewswire · January 8, 2026
RPM Reports Fiscal 2026 Second-Quarter Results
RPM International Inc. (NYSE: RPM), a world leader in specialty coatings, sealants and building materials, today reported financial results for its fiscal 2026 second quarter ended November 30, 2025.
By RPM International Inc. · Via Business Wire · January 8, 2026
Helen of Troy Limited Reports Third Quarter Fiscal 2026 Results
Helen of Troy Limited (NASDAQ: HELE), designer, developer, and worldwide marketer of branded consumer home, outdoor, beauty, and wellness products, today reported results for the three-month period ended November 30, 2025.
By Helen of Troy Limited · Via Business Wire · January 8, 2026
Lindsay Corporation Reports Fiscal 2026 First Quarter Results
Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, today announced results for its first quarter of fiscal 2026, which ended on November 30, 2025.
By Lindsay Corporation · Via Business Wire · January 8, 2026
Brookfield Asset Management to Host Fourth Quarter and Full Year 2025 Results Conference Call
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. today announced it will host its fourth quarter and full year 2025 conference call and webcast on Wednesday, February 4, 2026, at 10:00 a.m. ET.
By Brookfield Asset Management Ltd · Via GlobeNewswire · January 8, 2026
Bridge Specialty Group acquires the assets of Shoemaker & Besser Associates, Inc.
DAYTONA BEACH, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- J. Scott Penny, chief acquisitions officer of Brown & Brown, Inc. (NYSE:BRO), and Jack Brubaker and L. Allan Boyd, owners of Shoemaker & Besser Associates, Inc. (“Shoemaker & Besser”), today announced that a Bridge Specialty Group company and subsidiary of Brown & Brown, Inc. has acquired the assets of Shoemaker & Besser.
By Bridge Specialty Group LLC · Via GlobeNewswire · January 8, 2026
eDreams ODIGEO Secures Rulings, Ryanair Fined for Breach of Court Order and Forced to Cease Unlawful Practices
In two separate rulings secured by eDreams ODIGEO (hereinafter, ‘eDO'), the German Court not only penalised Ryanair for its disobedience to court orders but also declared several of the airline's core commercial practices unlawful.
By eDreams ODIGEO · Via Business Wire · January 8, 2026